Novel hydrazones derived from anthranilic acid as potent cholinesterases and α‐glycosidase inhibitors: Synthesis, characterization, and biological effects
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Feyzi Sinan Tokalı und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey. Hauptthemen laut MEDLINE: Butyrylcholinesterase, Acetylcholinesterase, ortho-Aminobenzoates. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Bartin Üniversitesi, Scientific Research Projects Commission, Bartin University.
Abstract (Originalsprache)
N ‐substitued anthranilic acid derivatives are commonly found in the structure of many biologically active molecules. In this study, new members of hydrazones derived from anthranilic acid (1−15) were synthesized and investigated their effect on some metabolic enzymes such as acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α‐glycosidase (α‐Gly). Results indicated that all the molecules exhibited potent inhibitory effects against all targets as compared to the standard inhibitors, revealed by IC 50 values. K i values of compounds for AChE, BChE, and α‐Gly enzymes were obtained in the ranges 66.36 ± 8.30–153.82 ± 13.41, 52.68 ± 6.38–113.86, and 2.13 ± 0.25–2.84 nM, respectively. The molecular docking study was performed for the most active compounds to the determination of ligand–enzyme interactions. Binding affinities of the most active compound were found at the range of –9.70 to –9.00 kcal/mol for AChE, –11.60 to –10.60 kcal/mol for BChE, and −10.30 to −9.30 kcal/mol for α‐Gly. Molecular docking simulations showed that the novel compounds had preferential interaction with AChE, BChE, and α‐Gly. Drug‐likeness properties and ADMET (absorption, distribution, metabolism, excretion, and toxicity) analyzes of all synthesized compounds (1−15) were estimated and their toxic properties were evaluated as well as their therapeutic properties. Moreover, molecular dynamics simulations were carried out to understand the accuracy of the most potent derivatives of docking studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey.
- Department of Biotechnology, Faculty of Science, Bartin University, Bartin, Turkey.
- Department of Chemistry, Faculty of Arts and Sciences, Gaziantep University, Gaziantep, Turkey.
- Department of Bioinformatics and Computational Biology, Institute of Health Sciences, Gaziantep University, Gaziantep, Turkey.
- Department of Chemistry, Faculty of Sciences, Atatürk University, Erzurum, Turkey.
Förderung
- Bartin Üniversitesi
- Scientific Research Projects Commission, Bartin University
Zitieren
APA
Tokalı, F. S., Taslimi, P., Taskin-Tok, T., Karakuş, A., Sadeghian, N., & Gulçin, İ. (2024). Novel hydrazones derived from anthranilic acid as potent cholinesterases and α‐glycosidase inhibitors: Synthesis, characterization, and biological effects. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23521
Vancouver
Tokalı FS, Taslimi P, Taskin-Tok T, Karakuş A, Sadeghian N, Gulçin İ. Novel hydrazones derived from anthranilic acid as potent cholinesterases and α‐glycosidase inhibitors: Synthesis, characterization, and biological effects. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23521
BibTeX
@article{Tokal2024,
author = {Tokalı, Feyzi Sinan and Taslimi, Parham and Taskin-Tok, Tugba and Karakuş, Ahmet and Sadeghian, Nastaran and Gulçin, İlhami},
title = {Novel hydrazones derived from anthranilic acid as potent cholinesterases and α‐glycosidase inhibitors: Synthesis, characterization, and biological effects},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23521}
}
EUVIMED